Lucy Therapeutics, Inc. announced they raised $12.5 million in additional funding led by existing and new investors. The company is working to develop novel therapies based on mitochondrial small-molecule treatments and diagnostic biomarkers for complex neurological diseases.
Lucy Therapeutics was a MassNextGen awardee. The MLSC initiative is designed to support underrepresented entrepreneurs by providing them with a year-long customized package of support, which includes non-dilutive grant funding and access to a network of seasoned professionals from the life sciences ecosystem helping them to refine their business strategies and effectively raise capital.